Vacuolar ATPase (V-ATPase; ATP6) is a highly conserved enzyme complex critical for acidifying various intracellular compartments in eukaryotic cells, such as vacuoles, lysosomes, endosomes, and the Golgi apparatus. It functions by transporting protons (H+) across biological membranes using energy from ATP hydrolysis, thus establishing an electrochemical proton gradient. This proton gradient is essential for various cellular processes, including protein degradation, receptor-mediated endocytosis, and intracellular trafficking. The complex structure of V-ATPase is composed of multiple subunits, divided into the V1 domain responsible for ATP hydrolysis and the V0 domain responsible for proton translocation. The activity of V-ATPase is regulated by several mechanisms, including reversible disassembly of the V1 and V0 domains, phosphorylation, and interactions with various accessory proteins. Dysregulation of V-ATPase activity can lead to altered cellular homeostasis and has been implicated in various diseases.
Targeting the Vacuolar ATPase (V-ATPase; ATP6) for disruption or inhibition has been explored as a strategy to modulate its activity in pathological conditions. Small molecule inhibitors of V-ATPase, such as Bafilomycin A1 and Concanamycin A, bind to the V0 domain of the enzyme, inhibiting proton translocation and thereby disrupting the acidification process. Genetic approaches, including RNA interference (RNAi), have also been used to decrease the expression of specific V-ATPase subunits, providing another means of inhibition. Inhibiting V-ATPase can affect multiple cellular processes, given its role in endocytic and autophagic pathways, and has potential implications in altering disease progression.
Items 1 to 10 of 12 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | ¥1083.00 ¥2821.00 ¥8462.00 ¥16111.00 | 280 | |
巴佛洛霉素 A1 是一种存在于灰葡萄链霉菌中的天然产物。它是一种强效的选择性 V-ATPase A1 抑制剂,广泛用于研究 V-ATPase 的功能。 | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | ¥745.00 | 4 | |
质子泵抑制剂,可降低 H+ 离子浓度,通过减少底物的可用性间接削弱 V-ATPase C2 的活性。 | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | ¥316.00 ¥417.00 | 18 | |
抑制环氧化酶途径,减少对质子泵的需求,从而降低 V-ATPase C2 的活性。 | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | ¥733.00 ¥1828.00 ¥7333.00 ¥28769.00 | 109 | |
康加霉素 A是从链霉菌中分离出来的另一种 V-ATP 酶 A1 天然抑制剂。它在结构上与巴佛洛霉素 A1 有关,具有类似的抑制特性。 | ||||||
SB202190 hydrochloride | 350228-36-3 | sc-222294 sc-222294A | 1 mg 5 mg | ¥1444.00 ¥5585.00 | 13 | |
p38 MAPK 抑制剂,可改变细胞内信号传导,导致 V-ATPase C2 的翻译和合成减少。 | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | ¥519.00 ¥1579.00 ¥7672.00 | 16 | |
表皮生长因子受体(FGFR)抑制剂,可下调 MAPK 通路,从而降低 V-ATPase C2 的表达。 | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | ¥1241.00 ¥4964.00 ¥7446.00 ¥13538.00 | 2 | |
MLCK 抑制剂,可减少钙介导的细胞内信号传导,间接影响 V-ATPase C2 的活性。 | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | ¥2008.00 | 25 | |
CaMKII 抑制剂,可调节钙信号,间接影响囊泡酸化过程中对 V-ATPase C2 的需求。 | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | ¥293.00 ¥1038.00 ¥1354.00 ¥3497.00 ¥5641.00 ¥10244.00 ¥20545.00 | 46 | |
酪氨酸激酶抑制剂可影响信号级联,进而降低 V-ATPase C2 的表达水平。 | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | ¥1038.00 ¥2053.00 | 71 | |
PKA 抑制剂,可降低 cAMP 水平,从而通过 cAMP 依赖性途径降低 V-ATPase C2 的活化。 |